Claims

1. A crystalline form of a compound according to formula Ib. ##STR00008##

2. A process for preparing a polymorph of the crystalline form of claim 1, comprising crystallizing the compound (Ib) from THF, water, and nBuAc.

3. A polymorphic crystalline form (Form I) of the compound of claim 1 with an x-ray powder diffraction trace having a D-spacing essentially as shown: TABLE-US-00025 D-space I/I_o × 100 15.1 100.0 10.9 21.9 6.0 39.5 3.2 30.0

4. A polymorphic crystalline form (Form II) of the compound of claim 1 with an x-ray powder diffraction trace having a D-spacing essentially as shown: TABLE-US-00026 D-space I/I_o × 100 13.2 100.0 9.8 44.0 7.9 20.9 7.6 17.3 5.3 30.5

5. A polymorphic crystalline form (Form III) of the compound of claim 1 with an x-ray powder diffraction trace having a D-spacing essentially as shown: TABLE-US-00027 D-space I/I_o × 100 6.8 100.0 4.6 44.0 4.4 31.7 4.1 31.5 3.7 36.9 3.6 42.7 3.4 32.3

6. A polymorphic crystalline form (Form IV) of the compound of claim 1 with an x-ray powder diffraction trace having a D-spacing essentially as shown: TABLE-US-00028 D-space I/I_o × 100 12.9 43.0 11.3 100.0 4.6 25.6 4.0 23.7

7. A polymorphic crystalline form (Form V) of the compound of claim 1 with an x-ray powder diffraction trace having a D-spacing essentially as shown: TABLE-US-00029 D-space I/I_o × 100 13.9 56.2 10.8 58.2 10.1 100 5.7 87.7 5.5 45.4 3.4 54.9 3.2 27.5

8. A polymorphic crystalline form (Form VI) of the compound of claim 1 with an x-ray powder diffraction trace having a D-spacing essentially as shown: TABLE-US-00030 D-space I/I_o × 100 13.4 100.0 10.9 38.4 9.8 48.4 5.7 40.1 5.4 37.6 3.6 41.8 3.4 38.8 3.2 35.4

9. A polymorphic crystalline form (Form VII) of the compound of claim 1 with an x-ray powder diffraction trace having a D-spacing essentially as shown: TABLE-US-00031 D-space I/I_o × 100 13.9 100.0 10.2 33.4 5.6 33.0 3.7 26.2 3.4 36.7 3.3 27.9

10. A polymorphic crystalline form (Form VIII) of the compound of claim 1 with an x-ray powder diffraction trace having a D-spacing essentially as shown: TABLE-US-00032 D-space I/I_o × 100 7.2 65.6 6.7 34.3 6.1 45.3 4.7 53.9 4.1 45.2 3.9 100.0 3.4 43.4

11. A polymorphic crystalline form (Form IX) of the compound of claim 1 with an x-ray powder diffraction trace having a D-spacing essentially as shown: TABLE-US-00033 D-space I/I_o × 100 12.6 39.1 6.6 58.9 6.0 68.9 4.6 100.0 4.0 57.7 3.9 35.4 3.3 32.4

12. A process for preparing the polymorphic crystalline form (Form III) of claim 5 comprising crystallizing the compound (Ib) from THF/water/n-butanol/n-butyl acetate, THF/nBuAc, butanone, or methyl isobutyl ketone.

13. A process for preparing the the polymorphic crystalline form (Form VIII) of claim 10 comprising crystallizing the compound (Ib) from THF/water/butyl acetate, acetonitrile, acetonitrile/water, or isopropanol/water.

14. A process for preparing the polymorphic crystalline form (Form IX) of claim 11 comprising crystallizing the compound (Ib) from acetonitrile.

15. A polymorphic crystalline form of a compound according to formula Ib prepared in accordance with the process of claim 2.

16. A method of treating a disease associated with HIV comprising administering to a patient in need thereof, a therapeutically effective amount of a polymorph of the crystalline form of claim 1.

17. The method of claim 16, further comprising administering an immune system modulator or an antiviral compound.

18. A method of treating a disease associated with HIV comprising administering to a patient in need thereof, a therapeutically effective amount of the amorphous state of Ib.

19. The method of claim 18, further comprising administering an immune system modulator or an antiviral compound.

20. A pharmaceutical composition comprising a polymorph of the crystalline form of claim 1, in admixture with at least one pharmaceutically acceptable carrier, diluent or excipient.

21. A pharmaceutical composition comprising of the amorphous state of Ib in admixture with at least one pharmaceutically acceptable carrier, diluent or excipient.